Depen Related Published Studies
Well-designed clinical trials related to Depen (Penicillamine)
Oral D-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: a randomized, placebo-controlled trial. [2010.09]
Oral D-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants: a randomized, placebo-controlled trial. [2010.04.16]
Well-designed clinical trials possibly related to Depen (Penicillamine)
Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial. [2010.05]
Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials. [2009.08]
Systematic review: clinical efficacy of chelator agents and zinc in the initial treatment of Wilson disease. [2009.05.01]
Other research related to Depen (Penicillamine)
D-Penicillamine for preventing retinopathy of prematurity in preterm infants. [2013]
D-penicillamine, a potent melanogenesis inhibitor, lacks any depigmenting effect on black guinea pig skin: the first randomized, evaluator-blinded, vehicle-controlled, in vivo study. [2011.06]
D-penicillamine elastosis perforans serpiginosa: description of two cases and review of the literature. [2011.04.15]
Involvement of T helper 17 cells in D-penicillamine-induced autoimmune disease in Brown Norway rats. [2011.04]
Microalbuminuria in rheumatoid arthritis in the post penicillamine/gold era: association with hypertension, but not therapy or inflammation. [2011.04]
Administration of a novel penicillamine-bound membrane: a preventive and therapeutic treatment for abdominal adhesions. [2011.02.25]
Combination therapy with andrographolide and d-penicillamine enhanced therapeutic advantage over monotherapy with d-penicillamine in attenuating fibrogenic response and cell death in the periportal zone of liver in rats during copper toxicosis. [2011.01.01]
Penicillamine-induced elastosis perforans serpiginosa with abnormal "lumpy-bumpy" elastic fibers in lesional and non-lesional skin. [2011.01]
Systemic administration of D-penicillamine prevents the locomotor activation after intra-VTA ethanol administration in rats. [2010.10.11]
Gabapentin as a rescue drug in D-penicillamine-induced status dystonicus in patients with Wilson disease. [2010.09]
Oral complications associated with D-penicillamine treatment for Wilson disease: a clinicopathologic report. [2010.08]
Intracellular delivery of the reactive oxygen species generating agent D-penicillamine upon conjugation to poly-L-glutamic acid. [2010.06.07]
Wilson's disease: long-term follow-up of a cohort of 24 patients treated with D-penicillamine. [2010.05]
Copper and zinc in the serum, urine, and hair of patients with Wilson's disease treated with penicillamine and zinc. [2010.03]
Penicillamine as a potent protector against injurious effects of cigarette smoke in aerodigestive tract cancer. [2010]
Bidirectional effects of fentanyl on dendritic spines and AMPA receptors depend upon the internalization of mu opioid receptors. [2009.08]
Penicillamine-induced elastosis of the mucosal lip. [2009.04]
Treatment of periocular hyperpigmentation due to lead of kohl (surma) by penicillamine: a single group non-randomized clinical trial. [2009]
Bullous pemphigoid induced by penicillamine in a patient with Wilson disease. [2009]
Effect of D-penicillamine on liver fibrosis and inflammation in Wilson disease. [2008.12]
Hypothyroidism and dyshormonogenesis induced by D-penicillamine in children with Wilson's disease and healthy infants born to a mother with Wilson's disease. [2008.12]
Penicillamine therapy for pediatric cystinuria: experience from a cohort of American children. [2008.12]
Cyclic-AMP-dependent proliferation of a human osteoblast cell line (HOS cells) induced by hydroxyapatite: effect of exogenous nitric oxide. [2008.08]
A retrospective randomly selected cohort study of D-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. [2008.05]
Bone mineral density of children with Wilson disease: efficacy of penicillamine and zinc therapy. [2008.02]
Withdrawal of penicillamine from zinc sulphate-penicillamine maintenance therapy in Wilson's disease: promising, safe and cheap. [2008.01.15]
Effect of penicillamine and zinc on iron metabolism in Wilson's disease. [2007.12]
D-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease. [2007.11]
Effect of oral D-penicillamine vs. colchicine on experimentally induced peritoneal adhesions in rats. [2007.10]
Selectivity of delta- and kappa-opioid ligands depends on the route of central administration in mice. [2007.07]
Discontinuation of penicillamine in the absence of alternative orphan drugs (trientine-zinc): a case of decompensated liver cirrhosis in Wilson's disease. [2007.02]
D-Penicillamine administration and the incidence of retinopathy of prematurity. [2007.02]
Orally administered penicillamine is a potent inhibitor of neointimal and medial thickening in porcine saphenous vein-carotid artery interposition grafts. [2007.02]
Liquid chromatography/tandem mass spectrometry determination of (4S,2RS)-2,5,5-trimethylthiazolidine-4-carboxylic acid, a stable adduct formed between D-(-)-penicillamine and acetaldehyde (main biological metabolite of ethanol), in plasma, liver and brain rat tissues. [2007]
Other possibly related research studies
Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trials. [2010.10.01]
Persistence with treatment in patients with Wilson disease. [2010.05]
Perioperative management of the patient with rheumatoid arthritis. [2010.04]
Hypoxia inducible factor-1 improves the negative functional effects of natriuretic peptide and nitric oxide signaling in hypertrophic cardiac myocytes. [2010.07.03]
Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. [2010.06]
Clinical features and therapeutic response in Taiwanese children with Wilson's disease: 12 years of experience in a single center. [2010.04]
Evidence for a role of opioids in epoxyeicosatrienoic acid-induced cardioprotection in rat hearts. [2010.06]
Clinical features and outcomes in patient with antineutrophil cytoplasmic autoantibody-positive glomerulonephritis associated with propylthiouracil treatment in Siriraj Hospital. [2010.01]
[Study on the sensitizing potential of shuanghuanglian injection using poplite lymph node assay in C57BL/6J mice] [2010.01]
Wilson disease: histopathological correlations with treatment on follow-up liver biopsies. [2010.03.28]
Involvement of L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of bis selenide in the mouse tail suspension test. [2010.06.10]
Activation of AMP-activated protein kinase by 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside in the muscle microcirculation increases nitric oxide synthesis and microvascular perfusion. [2010.06]
Copper(II)-selective chelation improves function and antioxidant defences in cardiovascular tissues of rats as a model of diabetes: comparisons between triethylenetetramine and three less copper-selective transition-metal-targeted treatments. [2010.06]
Evaluation of Cuprimine and Syprine for decorporation of (60)Co and (210)Po. [2010.03]
Oral lichenoid drug reaction associated with antihypertensive and hypoglycemic drugs. [2010.01]
Wilson's disease--a rare psychiatric presentation. [2009.07]
Nociceptive behaviour upon modulation of mu-opioid receptors in the ventrobasal complex of the thalamus of rats. [2010.03]
Poisoning of workers working in small lead-based units. [2008.12]
Evaluation and treatment of wrist drop in a patient due to lead poisoning: case report. [2009.12]
A prolonged protein kinase C-mediated, opioid-related antinociceptive effect of st John's Wort in mice. [2010.02]
[Case of goodpasture syndrome associated with minimal change nephrotic syndrome (MCNS) in a patient with rheumatoid arthritis (RA)] [2009]
Thiolated chitosan nanoparticles as an oral delivery system for Amikacin: in vitro and ex vivo evaluations. [2009.08]
Downregulation of CREB-binding protein expression sensitizes endothelial cells to serum-deprived apoptosis: important role of nitric oxide. [2010.04]
Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier. [2010.01]
An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists. [2009.08]
Cystinuria: the South Indian experience. [2009.12]
Long-term exclusive zinc monotherapy in symptomatic Wilson disease: experience in 17 patients. [2009.11]
Radiographic repair in three Japanese patients with rheumatoid arthritis treated with bucillamine. [2009]
Roles of opioid receptor subtypes in mediating alcohol-seeking induced by discrete cues and context. [2009.08]
The peripheral administration of a nitric oxide donor potentiates the local antinociceptive effects of a DOR agonist during chronic inflammatory pain in mice. [2009.10]
Treatment of Wilson's disease with tetrathiomolybdate: V. Control of free copper by tetrathiomolybdate and a comparison with trientine. [2009.08]
Protective mechanisms of NO preconditioning against NO-induced apoptosis in H9c2 cells: role of PKC and COX-2. [2009.08]
Role of the opioid system in incentive downshift situations. [2009.10]
Profile of acute mixed organophosphorus poisoning. [2009.06]
Diagnosis and treatment of polonium poisoning. [2009.05]
The role of telencephalic NO and cGMP in avoidance conditioning in goldfish (Carassius auratus). [2009.06]
Hepatitis C-associated rheumatic disorders. [2009.02]
Status epilepticus in Wilson's disease. [2009.06]
Long-term outcome in Serbian patients with Wilson disease. [2009.07]
A 15-year-old girl with severe hemolytic Wilson's crisis recovered without transplantation after extracorporeal circulation with the Prometheus system. [2009]
[Effects of artemether and dihydroarteannuin on mouse model of scleroderma] [2009.01]
Ankylosing spondylitis and systemic sclerosis: a rare combination. [2009.05]
[Acute recurrent hemolytic anemia as the first manifestation of Wilson's disease: Report of a case] [2009.03]
Ethanol-induced social facilitation in adolescent rats: role of endogenous activity at mu opioid receptors. [2009.06]
Correlation of in vitro and in vivo kinetics of nitric oxide donors in ocular tissues. [2009.04]
[Effect of disease modifying anti-rheumatic drugs on radiographic progression in rheumatoid arthritis] [2009.03]
[Wilson disease] [2009.07]
[Wilson's disease in paediatric age: diagnosis and treatment. Recent advances] [2008.11]
Nitric oxide effects on the function of aged cells ex vivo and in vivo. [2008.11]
Wilson disease in children: analysis of 57 cases. [2009.01]
Disease modifying anti-rheumatic drugs in people with cystic fibrosis-related arthritis. [2009.01.21]
Recent advances in the treatment of systemic sclerosis. [2009.06]
Acetaldehyde sequestering prevents ethanol-induced stimulation of mesolimbic dopamine transmission. [2009.03.01]
Triethylene tetramine dihydrochloride (trientine) in children with Wilson disease: experience at King's College Hospital and review of the literature. [2009.09]
[Risk factors and prevention of retinopathy of prematurity] [2008.12]
Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. [2009.07]
Serum copper (cu) alterations in pulmonary tuberculosis patients under treatment with ethambutol. [2009.05]
Parthenogenetic activation of pig oocytes using pulsatile treatment with a nitric oxide donor. [2010.06]
Wilson disease as a cause of liver injury in cystic fibrosis. [2009.01]
[Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment] [2008.08]
Juvenile localised scleroderma: a retrospective review of response to systemic treatment. [2008.12]
The stiff skin syndrome: case series, differential diagnosis of the stiff skin phenotype, and review of the literature. [2008.10]
|